Evidence map›Paper›PMID 35955529›Full record

ReviewInternational journal of molecular sciences2022

Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy?

Grégoire B Morand, Isabel Cardona, Sara Brito Silva Costa Cruz, Alex M Mlynarek, Michael P Hier, Moulay A Alaoui-Jamali, Sabrina Daniela da Silva

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. HPV-related diseases in male patients: an underestimated conundrum.Journal of endocrinological investigation · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Grégoire B MorandDepartment of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Isabel CardonaDepartment of Obstetrics and Gynecology, Montreal University Health Center, McGill University, Montreal, QC H3T 1E2, Canada.
Sara Brito Silva Costa CruzDepartment of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Alex M MlynarekDepartment of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Michael P HierDepartment of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Moulay A Alaoui-JamaliSegal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Sabrina Daniela da SilvaDepartment of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.ORCID 0000-0002-3742-2819
Jewish General Hospital · CAMcGill University Health Centre · CAUniversidade Federal da Paraíba · BR

Funding

CIHR 2022-2027Coordenação de Aperfeicoamento de Pessoal de Nível Superior SCDFATD-CBIE-FMPB 2022FRQS/RSBO#35376 258000 and 258259
6 · The paper itself

Abstract

The rise in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has prompted a quest for further understanding of the role of high-risk HPV in tumor initiation and progression. Patients with HPV-positive OPSCC (HPV+ OPSCC) have better prognoses than their HPV-negative counterparts; however, current therapeutic strategies for HPV+ OPSCC are overly aggressive and leave patients with life-long sequalae and poor quality of life. This highlights a need for customized treatment. Several clinical trials of treatment de-intensification to reduce acute and late toxicity without compromising efficacy have been conducted. This article reviews the differences and similarities in the pathogenesis and progression of HPV-related OPSCC compared to cervical cancer, with emphasis on the role of prophylactic and therapeutic vaccines as a potential de-intensification treatment strategy. Overall, the future development of novel and effective therapeutic agents for HPV-associated head and neck tumors promises to meet the challenges posed by this growing epidemic.

Indexed as

AlphapapillomavirusHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsUterine Cervical NeoplasmsVaccinesFemaleHumansPapillomaviridaeQuality of LifeSquamous Cell Carcinoma of Head and NeckVaccineshead and neck neoplasmsimmune checkpoint inhibitorsimmunizationintensity-modulatedpapillomavirus infectionsradiotherapyvaccines

Identifiers

PMID35955529
PMCPMC9368783
OpenAlexW4289134995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.